CureDuchenne Ventures is a proud funder and collaborator in Entrada Therapeutic’s Duchenne program, as was announced today as part of Entrada’s latest financing from a group of investors. Entrada will use the funding from CureDuchenne to advance its lead Duchenne exon-skipping oligonucleotide program to the clinic.
Entrada Therapeutics is a biotechnology company based in Boston, Massachusetts, and their technology can be applied to a wide array of diseases. CureDuchenne is pleased that Entrada has decided to focus on Duchenne muscular dystrophy for their lead indication.
Debra Miller, Founder and CEO of CureDuchenne said “CureDuchenne continues to believe in the promise of safe and effective exon-skipping therapies to restore dystrophin in cardiac and skeletal muscle, and the importance of having a robust pipeline with multiple ‘shots on goal.’ We are thrilled that Entrada’s team of dedicated leaders have set their sights on Duchenne as their lead indication, and look forward to how their program progresses.”